Ionis Pharmaceuticals Stock (NASDAQ:IONS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$38.76

52W Range

$35.95 - $54.44

50D Avg

$41.60

200D Avg

$43.87

Market Cap

$6.06B

Avg Vol (3M)

$1.55M

Beta

0.38

Div Yield

-

IONS Company Profile


Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

927

IPO Date

May 17, 1991

Website

IONS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
SPINRAZA Royalties$240.38M--
Licensing and Other Royalties$33.30M$30.99M$19.12M
Other Commercial$68.21M--
Product$34.91M$30.05M-
Research and Development Revenue$479.06M$284.01M-
Commercial$308.59M$303.36M$342.39M
Collaborative Agreement Revenue$352.66M$207.22M-
Spinraza Royalties-$242.31M$267.78M
Eplontersen Joint Development Revenue-$76.79M-
Research and Development Revenue Under Collaborative Agreements--$468.06M
TEGSEDI and WAYLIVRA--$55.50M

Fiscal year ends in Dec 23 | Currency in USD

IONS Financial Summary


Dec 23Dec 22Dec 21
Revenue$787.65M$587.00M$810.00M
Operating Income$-353.73M$-411.00M$-30.00M
Net Income$-366.29M$-270.00M$-29.00M
EBITDA$-322.84M$-561.00M$-21.00M
Basic EPS$-2.56$-1.90$-0.21
Diluted EPS$-2.56$-1.90$-0.21

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 01, 24 | 4:52 PM
Q1 24May 07, 24 | 12:00 AM
Q4 23Feb 21, 24 | 4:47 PM

Peer Comparison


TickerCompany
INCYIncyte Corporation
ARWRArrowhead Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
IOVAIovance Biotherapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
EXELExelixis, Inc.
HALOHalozyme Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.
ALNYAlnylam Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
VKTXViking Therapeutics, Inc.
KRYSKrystal Biotech, Inc.
MDGLMadrigal Pharmaceuticals, Inc.